Cargando…

Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study

OBJECTIVE: Bladder urothelial carcinoma (BUC) is a common urological malignancy with molecular heterogeneity. However, the genetic feature of Chinese BUC patients is still not well-identified. METHODS: We performed deep sequencing by a large panel (450 genes) on 22 BUC samples and using matched norm...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dong-Yang, Yang, Fei, Liao, Wei-Qiang, Zhou, Xiang-Fu, Li, Wen-Biao, Cai, Jia-Rong, Liu, Bo-Long, Luo, Yun, Zhan, Hai-Lun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160294/
https://www.ncbi.nlm.nih.gov/pubmed/34055593
http://dx.doi.org/10.3389/fonc.2021.538927
_version_ 1783700252842262528
author Li, Dong-Yang
Yang, Fei
Liao, Wei-Qiang
Zhou, Xiang-Fu
Li, Wen-Biao
Cai, Jia-Rong
Liu, Bo-Long
Luo, Yun
Zhan, Hai-Lun
author_facet Li, Dong-Yang
Yang, Fei
Liao, Wei-Qiang
Zhou, Xiang-Fu
Li, Wen-Biao
Cai, Jia-Rong
Liu, Bo-Long
Luo, Yun
Zhan, Hai-Lun
author_sort Li, Dong-Yang
collection PubMed
description OBJECTIVE: Bladder urothelial carcinoma (BUC) is a common urological malignancy with molecular heterogeneity. However, the genetic feature of Chinese BUC patients is still not well-identified. METHODS: We performed deep sequencing by a large panel (450 genes) on 22 BUC samples and using matched normal bladder tissue as control. Genomic alterations (GAs), pathways and Tumor Mutation Burden (TMB) were investigated. RESULTS: The frequencies of GAs (TERT, 54.5%; CREBBP, 27.3%; GATA3, 22.7%; BRAF, 18.2%; TEK, 18.2% and GLI1, 18.2%) were significantly higher in Chinese than Western BUC patients. Other GAs’ frequencies were in accordance with previous study (TP53, 50.0%; KDM6A, 31.8%; KMT2D, 22.7%; etc.). Besides, we detected gene amplification in ERBB2, FRS2, FAS, etc. The gene fusion/rearrangement took place in the chromosome 11, 12, 14, 17, 19, 22, and Y. Other than cell cycle and PI3K-AKT-mTOR, mutated genes were more associated with the transcription factor, chromatin modification signaling pathways. Interestingly, the TMB value was significantly higher in the BUC patients at stages T1–T2 than T3–T4 (P = 0.025). CONCLUSION: Deep genomic sequencing of BUC can provide new clues on the unique GAs of Chinese patients and assist in therapeutic decision.
format Online
Article
Text
id pubmed-8160294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81602942021-05-29 Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study Li, Dong-Yang Yang, Fei Liao, Wei-Qiang Zhou, Xiang-Fu Li, Wen-Biao Cai, Jia-Rong Liu, Bo-Long Luo, Yun Zhan, Hai-Lun Front Oncol Oncology OBJECTIVE: Bladder urothelial carcinoma (BUC) is a common urological malignancy with molecular heterogeneity. However, the genetic feature of Chinese BUC patients is still not well-identified. METHODS: We performed deep sequencing by a large panel (450 genes) on 22 BUC samples and using matched normal bladder tissue as control. Genomic alterations (GAs), pathways and Tumor Mutation Burden (TMB) were investigated. RESULTS: The frequencies of GAs (TERT, 54.5%; CREBBP, 27.3%; GATA3, 22.7%; BRAF, 18.2%; TEK, 18.2% and GLI1, 18.2%) were significantly higher in Chinese than Western BUC patients. Other GAs’ frequencies were in accordance with previous study (TP53, 50.0%; KDM6A, 31.8%; KMT2D, 22.7%; etc.). Besides, we detected gene amplification in ERBB2, FRS2, FAS, etc. The gene fusion/rearrangement took place in the chromosome 11, 12, 14, 17, 19, 22, and Y. Other than cell cycle and PI3K-AKT-mTOR, mutated genes were more associated with the transcription factor, chromatin modification signaling pathways. Interestingly, the TMB value was significantly higher in the BUC patients at stages T1–T2 than T3–T4 (P = 0.025). CONCLUSION: Deep genomic sequencing of BUC can provide new clues on the unique GAs of Chinese patients and assist in therapeutic decision. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8160294/ /pubmed/34055593 http://dx.doi.org/10.3389/fonc.2021.538927 Text en Copyright © 2021 Li, Yang, Liao, Zhou, Li, Cai, Liu, Luo and Zhan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Dong-Yang
Yang, Fei
Liao, Wei-Qiang
Zhou, Xiang-Fu
Li, Wen-Biao
Cai, Jia-Rong
Liu, Bo-Long
Luo, Yun
Zhan, Hai-Lun
Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title_full Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title_fullStr Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title_full_unstemmed Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title_short Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study
title_sort deep genomic sequencing of bladder urothelial carcinoma in southern chinese patients: a single-center study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160294/
https://www.ncbi.nlm.nih.gov/pubmed/34055593
http://dx.doi.org/10.3389/fonc.2021.538927
work_keys_str_mv AT lidongyang deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT yangfei deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT liaoweiqiang deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT zhouxiangfu deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT liwenbiao deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT caijiarong deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT liubolong deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT luoyun deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy
AT zhanhailun deepgenomicsequencingofbladderurothelialcarcinomainsouthernchinesepatientsasinglecenterstudy